Skip to main content

Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding.

  • 2012-11-27
  • Journal of Parenteral and Enteral Nutrition 37(5)
    • H. Akatsu
    • N. Iwabuchi
    • J. Xiao
    • Z. Matsuyama
    • R. Kurihara
    • K. Okuda
    • Takayuki Yamamoto
    • M. Maruyama

Abstract

Background: Immune system function declines with age. We evaluated the effects of supplementation with the probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in the elderly.

Materials and methods: In a double-blind study, 45 elderly patients fed by enteral tube feeding (mean [SD] age 81.7 [8.7] years) were given BB536 (n = 23) or a placebo powder (n = 22) for 12 weeks and were observed for an additional 4 weeks posttreatment. At week 4, all patients received an influenza vaccination (A/H1N1, A/H3N2, and B). Clinical data were assessed, including body temperature, bowel movements, fecal microbiota, and immunological biomarkers in blood.

Results: BB536 intake significantly increased cell numbers of bifidobacteria in fecal microbiota. There was a tendency toward an increase (P = .085 at week 4 and P = .070 at week 16) of serum IgA in the BB536 group compared with the placebo group. BB536 intake did not significantly affect hemagglutination inhibition (HI) titers in response to the influenza vaccine. Natural killer (NK) cell activity decreased significantly in the placebo group during the intervention but not in the BB536 group. Among those subjects with low NK cell activity (<55%, n = 10 for each group), a significant intergroup difference (P < .05) was observed in the changed values from baseline of NK cell activity at weeks 8 and 12.

Conclusions: These results shed new light on the potential of long-term ingestion of BB536 in increasing the cell number of bifidobacteria in intestinal microbiota and modulating immune function in the elderly.

Keywords: Bifidobacterium longum BB536; elderly; immune function; natural killer cell activity; probiotics; vaccine.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium bifidum BB01Increased Fecal Bifidobacterium LevelsBeneficial
Moderate
Bifidobacterium bifidum BB01Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium bifidum BB01Maintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium bifidum BB-06Improved Immune FunctionBeneficial
Moderate
Bifidobacterium bifidum BB-06Increased Bifidobacteria in Fecal MicrobiotaBeneficial
Large
Bifidobacterium bifidum BB-06Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium bifidum MAK53B66BIncreased Fecal Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium bifidum MAK53B66BIncreased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium bifidum MAK53B66BMaintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium bifidum MAK53B66BMaintenance of NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum B1-05Increased Fecal Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium longum B1-05Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum B1-05Increased Serum IgA LevelsBeneficial
Small
Bifidobacterium longum B1-05Maintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum BB536Increased Fecal Bifidobacteria NumbersBeneficial
Moderate
Bifidobacterium longum BB536Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum BB536Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum BB536No Significant Change in Hemagglutination Inhibition TitersNeutral
Small
Bifidobacterium longum BB536Stabilized Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum BI-05Increased Gut BifidobacteriaBeneficial
Large
Bifidobacterium longum BI-05Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum BI-05Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum BI-05Maintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum BL03Enhanced Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum BL03Increased Fecal Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium longum BL03Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum BL03Maintenance of NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum HA-135Increased Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium longum HA-135Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum HA-135Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum HA-135Stabilized Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum iVE-15Increased Fecal Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium longum iVE-15Increased NK Cell Activity in Individuals with Baseline Low NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum KABP-042Improved Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum KABP-042Increased Bifidobacteria in Fecal MicrobiotaBeneficial
Large
Bifidobacterium longum KABP-042Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum KABP-042Maintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum MAK34B12LIncreased Fecal BifidobacteriaBeneficial
Large
Bifidobacterium longum MAK34B12LIncreased Serum IgA LevelsBeneficial
Small
Bifidobacterium longum MM-2Increased Bifidobacteria in Intestinal MicrobiotaBeneficial
Large
Bifidobacterium longum MM-2Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum MM-2Maintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum Rosell-175Increased Intestinal Bifidobacterium LevelsBeneficial
Large
Bifidobacterium longum Rosell-175Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum Rosell-175Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum Rosell-175Maintenance of NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEImproved Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEIncreased Intestinal Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEIncreased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum Rosell-175 MEMaintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum SD-5588Increased Gut BifidobacteriaBeneficial
Large
Bifidobacterium longum SD-5588Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum SD-5588Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum SP54Increased Bifidobacteria Levels in Gut MicrobiotaBeneficial
Moderate
Bifidobacterium longum SP54Increased Serum IgA LevelsBeneficial
Small
Bifidobacterium longum SP54Maintenance of NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Increased Bifidobacteria in Fecal MicrobiotaBeneficial
Large
Bifidobacterium longum subsp. longum UABI-14Increased NK Cell ActivityBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum subsp. longum UABI-14Maintained Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum UABI-14Improved Natural Killer Cell ActivityBeneficial
Moderate
Bifidobacterium longum UABI-14Increased Fecal Bifidobacteria LevelsBeneficial
Moderate
Bifidobacterium longum UABI-14Increased Serum Immunoglobulin A (IgA) LevelsBeneficial
Small
Bifidobacterium longum UABI-14Maintained Natural Killer Cell ActivityBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.